Latest Breaking News On - Jianxiang wang - Page 1 : comparemela.com

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited kingdomAnn hematolJianxiang wangZhou yiShui weiBen atwell alex shawUnited kingdom medical research councilStock exchange of hong kongExchange commissionChina limitedNational cancer institutePhasei trialMenin inhibitorHematological malignanciesChinese academy

Apollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia Treatment

By Exec Edge Editorial Staff Apollomics Inc. (Nasdaq: APLM) said it completed patient enrollment in its Phase 3 bridging study for uproleselan in Chinese patients with relapsed or refractory acute myeloid leukemia. The study, conducted across 20 sites in Greater China, involved 140 adult patients and focused on evaluating the efficacy of uproleselan, an investigational […]

Jianxiang wangApollomics incUnion medical collegeChinese academy of medical sciencesExec edge editorialGreater chinaChinese academyMedical sciencesPeking union medical collegePatient enrollmentApollomics inc

Apollomics Inc : Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Apollomics Inc : Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesSean leousJianxiang wangPeter vozzoGuo liang yuApollomics incDrug administrationExchange commissionUnion medical collegeChinese national medical products administrationSecurities exchangeChinese academy of medical sciencesGreater chinaMainland chinaChinese academy

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

FOSTER CITY, Calif., Jan. 03, 2024 Apollomics Inc. , a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced the completion of.

United statesHong kongSean leousJianxiang wangPeter vozzoGuo liang yuExchange commissionUnion medical collegeChinese national medical products administrationSecurities exchangeChinese academy of medical sciencesApollomics incDrug administrationGreater chinaMainland chinaChinese academy

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesHong kongQian jiangJianyong liJianxiang wangPrnewswire ascentage pharmaHuafeng wangElias jabbourXiaojun huangJie jinKeshu zhouSikander ailawadhiXiaoyuan gongYifan zhaiLiposome mitoxantrone